News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bay Area's ReVance Therapeutics, Inc. (RVNC) Prices IPO At Top Of Range, Raises $96 Million


2/6/2014 7:51:42 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Wrinkle removing biotech company Revance Therapeutics raised $96 million in the Bay Area's second IPO of 2014 on Thursday. The Newark company led by CEO Dan Browne sold 6 million shares at $16 each and is expected to trade as RVNC on the Nasdaq on Thursday. Revance's market cap at its IPO price is about $284 million.

Help employers find you! Check out all the jobs and post your resume.

Read at Silicon Valley
Read at Nasdaq
Read at Seeking Alpha
Read at RTT News


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES